Microbiology results

Antimicrobial activity of Xydalba against Gram-positive clinical isolates from Europe6

Chart showing Xydalba microbiology results (JAC)

BHS, beta-haemolytic streptococci.

a) Includes: S. anginosus (28 isolates), S. anginosus group (5), Streptococcus bovis group (2), Streptococcus constellatus (14), Streptococcus intermedius (1), Streptococcus mitis/oralis (4), S. mitis group (5), S. oralis (5), Streptococcus parasanguinis (1), Streptococcus salivarius (1), Streptococcus sanguinis (1) and unspeciated VGS (2).

b) Includes: S. agalactiae (135 isolates), S. dysgalactiae (47), Streptococcus equisimilis (5), S. pyogenes (223), Group C streptococci (13), Group F streptococci (1) and Group G streptococci (42).

c) Modal MIC values are shown in bold. Underlining represents the percentage of susceptible isolates according to the FDA and EUCAST interpretative criteria (all ≤0.12 mg/L for susceptible). The breakpoint for S. anginosus group was utilized for VGS, and the S. pyogenes and S. agalactiae breakpoint was applied for BHS and S. dysgalactiae.

6 Mendes RE, Castanheira M, Farrell DJ, et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). J Antimicrob Chemother. 2016 Jan;71(1):276-8.